Infusion of Depleted T Cells Following Unrelated Donor Stem Cell Transplant (ICAT) (ICAT)
Adoptive Immunotherapy With CD25/71 Allodepleted Donor T Cells to Improve Immunity After Unrelated Donor Stem Cell Transplant
Sponsor: Medical Research Council
This PHASE1/PHASE2 trial investigates Haematological Malignancies and is currently completed. Medical Research Council leads this study, which shows 10 recorded versions since 2014 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Sep 2022 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
-
Jan 2021 — Sep 2022 [monthly]
Completed PHASE1_PHASE2
-
Dec 2020 — Jan 2021 [monthly]
Completed PHASE1_PHASE2
Status: Active Not Recruiting → Completed
▶ Show 5 earlier versions
-
Aug 2019 — Dec 2020 [monthly]
Active Not Recruiting PHASE1_PHASE2
Status: Recruiting → Active Not Recruiting
-
Nov 2018 — Aug 2019 [monthly]
Recruiting PHASE1_PHASE2
-
Jun 2018 — Nov 2018 [monthly]
Recruiting PHASE1_PHASE2
-
Jun 2017 — Jun 2018 [monthly]
Recruiting PHASE1_PHASE2
-
Jan 2017 — Jun 2017 [monthly]
Recruiting PHASE1_PHASE2
First recorded
Jul 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Medical Research Council
- University College, London
For direct contact, visit the study record on ClinicalTrials.gov .